Assignee
HUTCHISON MEDIPHARMA LTD
CN·26 granted patents·21 pending applications·22 citations·filing 2012–2025
Top patents by PatentIndex Score
47 records- 0195US11478474B22-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitorHUTCHISON MEDIPHARMA LTD·Filed 2021·Granted Oct 25, 2022·2 cites·15 claims
- 0289US2025099462A1Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use ThereforHUTCHISON MEDIPHARMA LTD·Filed 2024·Application pending·0 cites
- 0388US2024139182A1Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use ThereforHUTCHISON MEDIPHARMA LTD·Filed 2023·Application pending·0 cites
- 0486US10519142B2Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamideHUTCHISON MEDIPHARMA LTD·Filed 2015·Granted Dec 31, 2019·5 cites·20 claims
- 0583US10512645B2Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereforHUTCHISON MEDIPHARMA LTD·Filed 2018·Granted Dec 24, 2019·2 cites·18 claims
- 0682US9956218B2Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereforHUTCHISON MEDIPHARMA LTD·Filed 2016·Granted May 1, 2018·2 cites·10 claims
- 0780US10946014B2Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereforHUTCHISON MEDIPHARMA LTD·Filed 2019·Granted Mar 16, 2021·0 cites·2 claims
- 0879US10208066B2Imidazopyridazine compounds and their useHUTCHISON MEDIPHARMA LTD·Filed 2015·Granted Feb 19, 2019·4 cites·16 claims
- 0978US2024301077A1Anti-ox40 antibody and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2024·Application pending·0 cites
- 1078US2024398791A1Heteroaryl heterocyclic compounds and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2024·Application pending·0 cites
- 1177US12234211B2Cycloolefin substituted heteroaromatic compounds and their useHUTCHISON MEDIPHARMA LTD·Filed 2022·Granted Feb 25, 2025·0 cites·15 claims
- 1277US11046674B2Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamideHUTCHISON MEDIPHARMA LTD·Filed 2019·Granted Jun 29, 2021·2 cites·11 claims
- 1377US10052330B2Substituted pyrido[3,4-b]pyrazines as Syk inhibitorsHUTCHISON MEDIPHARMA LTD·Filed 2016·Granted Aug 21, 2018·2 cites·34 claims
- 1476US12030951B2Anti-OX40 antibody and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2022·Granted Jul 9, 2024·0 cites·13 claims
- 1576US11896592B2Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereforHUTCHISON MEDIPHARMA LTD·Filed 2021·Granted Feb 13, 2024·0 cites·12 claims
- 1674US2025223267A1Cycloolefin substituted heteroaromatic compounds and their useHUTCHISON MEDIPHARMA LTD·Filed 2025·Application pending·0 cites
- 1773US12173008B2Substituted piperazines as BTK inhibitorsHUTCHISON MEDIPHARMA LTD·Filed 2023·Granted Dec 24, 2024·0 cites·34 claims
- 1873US12070457B2Substituted pyridines, pyridazines, pyrimidines, and 1,2,3-triazines as bruton's tyrosine kinase inhibitorsHUTCHISON MEDIPHARMA LTD·Filed 2022·Granted Aug 27, 2024·0 cites·38 claims
- 1973US9701680B2Pyrimidine and pyridine compounds and their usageHUTCHISON MEDIPHARMA LTD·Filed 2014·Granted Jul 11, 2017·2 cites·23 claims
- 2072US2024391918A1Salts of a compound and the crystalline forms thereofHUTCHISON MEDIPHARMA LTD·Filed 2024·Application pending·0 cites
- 2172US2025361223A1Amide compounds and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2025·Application pending·0 cites
- 2271US12084441B2Salts of a compound and the crystalline forms thereofHUTCHISON MEDIPHARMA LTD·Filed 2022·Granted Sep 10, 2024·0 cites·8 claims
- 2371US10111875B2Pyrrolopyrimidine compounds and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2016·Granted Oct 30, 2018·1 cites·23 claims
- 2468US11655254B2Substituted piperazines as BTK inhibitorsHUTCHISON MEDIPHARMA LTD·Filed 2022·Granted May 23, 2023·0 cites·35 claims
- 2567US12180214B2Crystalline forms of (s)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinaseHUTCHISON MEDIPHARMA LTD·Filed 2023·Granted Dec 31, 2024·0 cites·18 claims
- 2666US12435062B2Amide compounds and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2021·Granted Oct 7, 2025·0 cites·20 claims
- 2766US11414390B2Cycloolefin substituted heteroaromatic compounds and their useHUTCHISON MEDIPHARMA LTD·Filed 2018·Granted Aug 16, 2022·0 cites·9 claims
- 2866US2023242657A1Anti-ox40 antibody and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2021·Application pending·0 cites
- 2960US11396507B2Salts of a compound and the crystalline forms thereofHUTCHISON MEDIPHARMA LTD·Filed 2018·Granted Jul 26, 2022·0 cites·21 claims
- 3058US2022073642A1Methods of using surufatinib in treating advanced pancreatic and extra-pancreatic neuroendocrine tumorsHUTCHISON MEDIPHARMA LTD·Filed 2021·Application pending·0 cites
- 3157US10369153B2Pyrrolopyrimidine compounds and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2018·Granted Aug 6, 2019·0 cites·6 claims
- 3257US2015368271A1Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereforHUTCHISON MEDIPHARMA LTD·Filed 2015·Application pending·0 cites
- 3355US11584750B2Crystalline forms of (S)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinaseHUTCHISON MEDIPHARMA LTD·Filed 2019·Granted Feb 21, 2023·0 cites·22 claims
- 3455US2022125789A1Pharmaceutical preparation of fruquintinib and use thereofHUTCHISON MEDIPHARMA LTD·Filed 2019·Application pending·0 cites
- 3554US10611777B2Imidazopyridazine compounds and their useHUTCHISON MEDIPHARMA LTD·Filed 2018·Granted Apr 7, 2020·0 cites·19 claims
- 3654US2024002388A1Pyrimidinone compounds and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2021·Application pending·0 cites
- 3754US2023151110A1Anti-cd47 antibody and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2021·Application pending·0 cites
- 3854US2024092774A1Heteroaromatic compounds and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2021·Application pending·0 cites
- 3951US2017152258A9Substituted Pyridopyrazines as Syk InhibitorsHUTCHISON MEDIPHARMA LTD·Filed 2013·Application pending·0 cites
- 4050US12492210B2Tricyclic compounds and their useHUTCHISON MEDIPHARMA LTD·Filed 2020·Granted Dec 9, 2025·0 cites·40 claims
- 4150US2015291593A1Novel heteroaryl and heterocycle compounds, compositions and methodsHUTCHISON MEDIPHARMA LTD·Filed 2013·Application pending·0 cites
- 4249US2015307520A1Novel heteroaryl and heterocycle compounds, compositions and methods thereofHUTCHISON MEDIPHARMA LTD·Filed 2013·Application pending·0 cites
- 4349US2015307491A1Substituted pyridopyrazines as syk inhibitorsHUTCHISON MEDIPHARMA LTD·Filed 2012·Application pending·0 cites
- 4448US2016052926A1Novel pyrimidine and pyridine compounds and usage thereofHUTCHISON MEDIPHARMA LTD·Filed 2013·Application pending·0 cites
- 4543US12559472B2Salts of a compound and the crystalline forms thereofHUTCHISON MEDIPHARMA LTD·Filed 2020·Granted Feb 24, 2026·0 cites·16 claims
- 4643US2018153890A1Pharmaceutical compositions and use thereofHUTCHISON MEDIPHARMA LTD·Filed 2016·Application pending·0 cites
- 4738US2019276439A1Method of treating solid tumorsHUTCHISON MEDIPHARMA LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when HUTCHISON MEDIPHARMA LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →